`
`About the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
`
`Home | Visit the NCCN Patient Site | About NCCN | Find a Member Institution | Login/Register | Contact Us
`
`NCCN
`Guidelines®
`
`NCCN
`Compendia
`
`NCCN
`Templates®
`
`Educational Events
`& Programs
`
`Subscriptions
`& Products
`
`Clinical & Business
`Resources
`
`NCCN
`Global
`
`NCCN Oncology
`Research Program
`
`Patient
`Resources
`
`Follow us on:
`
`
`
`Quick Links
`
`Clinicians
`NCCN Guidelines FREE
`®
`®
`NCCN Compendium
`
`®
`NCCN Biomarkers Compendium
`®
`NCCN Templates
`
`Educational Events
`
`CME/CE Programs
`
`NCCN Guidelines for Patients
`
`®
`
`NCCN Guidelines & Clinical Resources
`®
`About the NCCN Clinical Practice Guidelines in
`Oncology (NCCN Guidelines )
`®
`The National Comprehensive Cancer Network (NCCN ) is an alliance of 27 of the world's leading cancer
`®
`®
`centers, working together to develop treatment guidelines for most cancers, and dedicated to research that
`improves the quality, effectiveness, and efficiency of cancer care. NCCN offers a number of programs to
`give clinicians access to tools and knowledge that can help guide decisionmaking in the management of
`cancer.
`NCCN Clinical Practice Guidelines in Oncology (NCCN
`Guidelines )
`®
`
`Over the past 20 years, NCCN has developed an integrated suite of tools to improve the quality of cancer
`care. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) document evidencebased,
`®
`consensusdriven management to ensure that all patients receive preventive, diagnostic, treatment, and
`supportive services that are most likely to lead to optimal outcomes.
`
`The NCCN Guidelines are a comprehensive set of guidelines detailing the sequential management
`®
`decisions and interventions that currently apply to 97 percent of cancers affecting patients in the United
`States. In addition, separate guidelines provide recommendations for some of the key cancer prevention
`and screening topics as well as supportive care considerations. The NCCN Guidelines provide
`recommendations based on the best evidence available at the time they are derived. Because new data are
`published continuously, it is essential that the NCCN Guidelines also be continuously updated and revised
`to reflect new data and clinical information that may add to or alter current clinical practice standards. The
`intent of the NCCN Guidelines is to assist in the decisionmaking process of individuals involved in cancer
`care—including physicians, nurses, pharmacists, payers, patients and their families—with the ultimate goal
`of advancing patient care in the fight against cancer.
`
`The NCCN Guidelines are composed of several critical components, as follows:
`
`listing of panel members providing institutional affiliations and specialties;
`algorithms or decision pathways outlining the stepbystep clinical decisionmaking process for patient
`management;
`discussion text summarizing the data the recommendations are based upon and the important issues
`considered in interpreting the data and developing the algorithms;
`listing of references providing the evidence on which recommendations are based; and
`disclosure of potential conflicts of interest of panel members and NCCN headquarters staff.
`
`The NCCN Guidelines are developed and updated by 48 individual panels, comprising over 1,150 clinicians
`and oncology researchers from the 27 NCCN Member Institutions. These panel members are
`multidisciplinary, diseasespecific subspecialists who are both clinicians and researchers. In addition, each
`guideline undergoes annual institutional review where it is circulated for comment among the
`multidisciplinary faculty at each NCCN Member Institution.
`
`Further details on the Development and Update of the NCCN Guidelines are available, which provide
`information on the composition and roles of the NCCN Guidelines development group, policies for
`transparency and management of potential conflicts of interest, and the Guidelines development and
`updates process.
`
`NCCN Guidelines
`
`®
`
`About The NCCN Clinical Practice
`Guidelines in Oncology (NCCN
`Guidelines )
`®
`
`Development and Update of the NCCN
`Guidelines
`
`Recent Updates to NCCN Guidelines
`®
`
`NCCN Guidelines Panels Meeting
`Schedule
`
`NCCN Categories of Evidence and
`Consensus
`
`NCCN Guidelines Steering Committee
`®
`
`Transparency: Process and
`Recommendations
`
`Submission Request to the NCCN
`Guidelines Panels
`
`Submission Request History
`
`Permissions Requests
`
`EndUser License Agreement
`NCCN Disclosure Policies & Potential
`Conflicts of Interest
`
`NCCN Compendium
`®
`
`NCCN Biomarkers Compendium
`®
`
`NCCN Imaging AUC™
`
`NCCN Templates
`®
`
`NCCN Mobile Apps
`
`NCCN Guidelines with NCCN
`Evidence Blocks™
`
`NCCN Framework for Resource
`Stratification of NCCN Guidelines
`(NCCN Framework™)
`
`International Adaptations and
`Translations
`
`NCCN China Website
`
`NCCN Flash Updates™
`
`Online Catalog
`
`JNCCN — Journal of the National
`Comprehensive Cancer Network
`
`NCCN Disclosure Policies & Potential
`Conflicts of Interest
`
`Upcoming Events
`
`CME/CE Programs
`
`About NCCN
`
`|
`
`|
` Privacy Policy
`|
` NCCN Foundation
`|
` Patient Resources
`|
` NCCN Member Institutions
`275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
`Copyright © 2016 National Comprehensive Cancer Network, All Rights Reserved
`
` Legal Notices
`
`|
`
` Contact Us
`
`https://www.nccn.org/professionals/default.aspx
`
`1/1
`
`AVENTIS EXHIBIT 2138
`Mylan v. Aventis, IPR2016-00712